Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota

Neoplasia (United States)

Volumn 20, Issue 7, 2018, Pages 721-733

  Morgillo, Floriana ^a   Dallio, Marcello ^a   Della Corte, Carminia Maria ^a   Gravina, Antonietta Gerarda ^a   Viscardi, Giuseppe ^a   Loguercio, Carmelina ^a   Ciardiello, Fortunato ^a   Federico, Alessandro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOGLOBULIN A; REACTIVE OXYGEN METABOLITE;

CANCER GROWTH; CARCINOGENESIS; DYSBIOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFLAMMATORY DISEASE; INTESTINE FLORA; MALIGNANT NEOPLASM; MICROBIAL COMMUNITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SENESCENCE; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; CHRONIC DISEASE; COMPLICATION; GASTROINTESTINAL TUMOR; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATION; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TUMOR MICROENVIRONMENT;

EID: 85047775527     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2018.05.002     Document Type: Review

References (169)

1. Nathan, C, Points of control in inflammation. Nature 420 (2002), 846–852.
2. Ekbom, A, Helmick, C, Zack, M, Adami, HO, Ulcerative colitis and colorectal cancer — a population-based study. N Engl Med 323 (1990), 1228–1233.
3. David, H, Rudolf Virchow and modern aspects of tumor pathology. Pathol Res Pract 183 (1988), 356–364.
4. Cho, CH, Yu, J, From inflammation to cancer: advances in diagnosis and therapy for gastrointestinal and hepatological diseases. 2012, World Scientific, Singapore.
5. Mantovani, A, Allavena, P, Sica, A, Balkwill, F, Cancer-related inflammation. Nature 454 (2008), 436–444.
6. Yang, J, Nishihara, R, Zhang, X, Ogino, S, Qian, ZR, Energy sensing pathways: bridging type 2 diabetes and colorectal cancer?. J Diabetes Complications 31 (2017), 1228–1236.
7. Rodier, F, Coppe, JP, Patil, CK, Hoeijmakers, WA, Muñoz, DP, Raza, SR, Freund, A, Campeau, E, Davalos, AR, Campisi, J, Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11 (2009), 973–979.
8. Berg, RD, The indigenous gastrointestinal microflora. Trends Microbiol 4 (1996), 430–435.
9. Benson, AK, Kelly, SA, Legge, R, Ma, F, SJ, Low, J, Kim, M, Zhang, PL Oh, Nehrenberg, D, Hua, K et al., Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci U S A 107 (2010), 18933–18938.
10. Ottman, N, Smidt, H, de Vos, WM, Belzer, C, The function of our microbiota: who is out there and what do they do?. Front Cell Infect Microbiol, 2, 2012, 104.
11. De Filippo, C, Cavalieri, D, Di Paola, M, Ramazzotti, M, Poullet, JB, Massart, S, Collini, S, Pieraccini, G, Lionetti, P, Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
12. Fändriks, L, Roles of the gut in the metabolic syndrome: an overview. J Intern Med 281 (2017), 319–336.
13. Grenham, S, Clarke, G, Cryan, JF, Dinan, TG, Brain-gut-microbe communication in health and disease. Front Physiol, 2, 2011, 94.
14. Fiebiger, U, Bereswill, S, Heimesaat, MM, Dissecting the interplay between intestinal microbiota and host immunity in health and disease: lessons learned from germfree and gnotobiotic animal models. Eur J Microbiol Immunol (Bp) 6 (2016), 253–271.
15. Louis, P, Flint, HJ, Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 19 (2017), 29–41.
16. Wells, JM, Brummer, RJ, Derrien, M, MacDonald, TT, Troost, F, Cani, PD, Theodorou, V, Dekker, J, Méheust, A, de Wos, WM et al., Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol 312 (2017), G171–G193.
17. S, Wu, Rhee, KJ, Albesiano, E, Rabizadeh, S, Wu, X, Yen, HR, Huso, DL, Brancati, FL, Wick, E, McAllister, F et al., A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15 (2009), 1016–1022.
18. Aggarwal, BB, Vijayalekshmi, RV, Sung, B, Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long- term foe. Clin Cancer Res 15 (2009), 425–430.
19. Takahashi, H, Ogata, H, Nishigaki, R, Broide, DH, Karin, M, Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta and JNK1-dependent inflammation. Cancer Cell 17 (2010), 89–97.
20. Rogovskii, VS, The linkage between inflammation and immune tolerance: interfering with inflammation in cancer. Curr Cancer Drug Targets 17 (2017), 325–332.
21. Lin, WW, Karin, M, A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007), 1175–1183.
22. Smyth, MJ, Dunn, GP, Schreiber, RD, Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006), 1–50.
23. Bui, JD, Schreiber, RD, Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol 19 (2007), 203–208.
24. Jackaman, C, Tomay, F, Duong, L, Abdol Razak, NB, Pixley, FJ, Metharom, P, Nelson, DJ, Aging and cancer: The role of macrophages and neutrophils. Ageing Res Rev 36 (2017), 105–116.
25. Galon, J, Costes, A, Sanchez-Cabo, F, Kirilovsky, A, Mlecnik, B, Lagorce-Pagès, C, Tosolini, M, Camus, M, Berger, A, Wind, P et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
26. Laghi, L, Bianchi, P, Miranda, E, Balladore, E, Pacetti, V, Grizzi, F, Allavena, P, Torri, V, Repici, A, Santoro, A et al., CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 10 (2003), 877–884.
27. Swann, JB, Smyth, MJ, Immune surveillance of tumors. J Clin Invest 117 (2007), 1137–1146.
28. Roberts, SJ, Ng, BY, Filler, RB, Lewis, J, Glusac, EJ, Hayday, AC, Tigelaar, RE, Girardi, M, Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A 104 (2007), 6770–6775.
29. Aspord, C, Pedroza-Gonzalez, A, Gallegos, M, Tindle, S, Burton, EC, Su, D, Marches, F, Banchereau, J, Palucka, AK, Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204 (2007), 1037–1047.
30. Langowski, JL, Zhang, X, Wu, L, Mattson, JD, Chen, T, Smith, K, Basham, B, McClanahan, T, Kastelein, RA, Oft, M, IL-23 promotes tumour incidence and growth. Nature 442 (2006), 461–465.
31. Soucek, L, Lawlor, ER, Soto, D, Shchors, K, Swigart, LB, Evan, GI, Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13 (2007), 1211–1218.
32. Sparmann, A, Bar-Sagi, D, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 (2004), 447–458.
33. Vakkila, J, Lotze, MT, Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4 (2004), 641–648.
34. Karin, M, Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006), 431–436.
35. Kim, S, Takahashi, H, Lin, WW, Descargues, P, Grivennikov, S, Kim, Y, Luo, JL, Karin, M, Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457 (2009), 102–106.
36. Zitvogel, L, Apetoh, L, Ghiringhelli, F, Kroemer, G, Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (2008), 59–73.
37. Ammirante, M, Luo, JL, Grivennikov, S, Nedospasov, S, Karin, M, B cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464 (2010), 302–305.
38. Okazaki, IM, Kotani, A, Honjo, T, Role of AID in tumorigenesis. Adv Immunol 94 (2007), 245–273.
39. Colotta, F, Allavena, P, Sica, A, Garlanda, C, Mantovani, A, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009), 1073–1081.
40. Cooper, CS, Foster, CS, Concepts of epigenetics in prostate cancer development. Br J Cancer 100 (2009), 240–245.
41. Oguma, K, Oshima, H, Aoki, M, Uchio, R, Naka, K, Nakamura, S, Hirao, A, Saya, H, Taketo, MM, Oshima, M, Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 27 (2008), 1671–1681.
42. Maeda, S, Kamata, H, Luo, JL, Leffert, H, Karin, M, IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005), 977–990.
43. Sakurai, T, He, G, Matsuzawa, A, GY, Yu, Maeda, S, Hardiman, G, Karin, M, Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14 (2008), 156–165.
44. Falkwill, F, Mantovani, A, Inflammation and cancer: back to Virchow?. Lancet 357 (2001), 539–545.
45. Koehne, CH, Dubois, RN, COX-2 inhibition and colorectal cancer. Semin Oncol 31 (2004), 12–21.
46. Flossmann, E, Rothwell, PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 (2007), 1603–1613.
47. Chan, AT, Ogino, S, Fuchs, CS, Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356 (2007), 2131–2142.
48. Fosslien, E, Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 (2000), 3–21.
49. Subbaramaiah, K, Dannenberg, AJ, Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24 (2003), 96–102.
50. Terzic, J, Grivennikov, S, Karin, E, Karin, M, Inflammation and colon cancer. Gastroenterology 138 (2010), 2101–2114.e5.
51. Shigdar, S, Li, Y, Bhattacharya, S, O'Connor, M, Pu, C, Lin, J, Wang, T, Xiang, D, Kong, L, Wei, MQ et al., Inflammation and cancer stem cells. Cancer Lett 345 (2014), 271–278.
52. Romano, M, De Francesco, F, Pirozzi, G, Gringeri, E, Boetto, R, Di Domenico, M, Zavan, B, Ferraro, GA, Cillo, U, Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2 (2015), 443–456.
53. Romano, M, De Francesco, F, Gringeri, E, Giordano, A, GA Ferraro, M, Domenico, DI, Cillo, U, Tumor microenvironment versus cancer stem cells in cholangiocarcinoma: synergistic effects?. J Cell Physiol 231 (2016), 768–776.
54. Popivanova, BK, Kitamura, K, Wu, Y, Kondo, T, Kagaya, T, Kaneko, S, Oshima, M, Fujii, C, Mukaida, N, Blocking TNF- alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118 (2008), 560–570.
55. Li, Y, Deuring, J, Peppelenbosch, MP, Kuipers, EJ, de Haar, C, van der Woude, CJ, IL6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33 (2012), 1889–1896.
56. Isomoto, H, Mott, JL, Kobayashi, S, Werneburg, NW, Bronk, SF, Haan, S, Gores, GJ, Sustained IL6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132 (2007), 384–996.
57. Ellenrieder, V, Buck, A, Gress, TM, TGFbeta-regulated transcriptional mechanisms in cancer. Int J Gastrointest Cancer 31 (2002), 61–69.
58. Zavadil, J, Bottinger, EP, TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24 (2009), 5764–5774.
59. Laurent, C, Svrcek, M, Flejou, JF, Chenard, MP, Duclos, B, Freund, JN, Reimund, JM, Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease- associated colorectal cancer. Inflamm Bowel Dis 17 (2011), 232–240.
60. Chang, CL, Marra, G, Chauhan, DP, Ha, HT, Chang, DK, Ricciardiello, L, Randolph, A, Carethers, JM, Boland, CR, Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 283 (2002), C148–C154.
61. Gerrits, MM, Chen, M, Theeuwes, M, van Dekken, H, Sikkema, M, Steyerberg, EW, Lingsma, HF, Siersema, PD, Xia, B, Kurster, JG et al., Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. Cell Oncol (Dordr) 34 (2011), 107–117.
62. Toyota, M, Ho, C, Ahuja, N, Jair, KW, Li, Q, Ohe-Toyota, M, Baylin, SB, Issa, JP, Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59 (1999), 2307–2312.
63. AS Fleisher, M, Esteller, N, Harpaz, A, Leytin, A, Rashid, Y Xu, Liang, J, Stine, OC, Yin, J, Zou, TT et al., Microsatellite instability in inflammatory bowel disease- associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH11. Cancer Res 60 (2000), 4864–4868.
64. Anthonisen, NR, Connett, JE, Kiley, JP, Altose, MD, Bailey, WC, Buist, AS, Conway, WA Jr., Enright, PL, Kanner, RE, O'Hara, P et al., Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994), 1497–1505.
65. Cosio, M, Ghezzo, H, Hogg, JC, Corbin, R, Loveland, M, Dosman, J, Macklem, PT, The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 298 (1978), 1277–1281.
66. Franklin, WA, Gazdar, AF, Haney, J, Wistuba, II, La Rosa, FG, Kennedy, T, Ritchey, DM, Miller, YE, Widely dispersed p 53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 100 (1997), 2133–2137.
67. Minna, JD, Fong, K, Zochbauer-Muller, S, Gazdar, AF, Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 8:Suppl. 1 (2002), S41–6.
68. Wistuba, II, Mao, L, Gazdar, AF, Smoking molecular damage in bronchial epithelium. Oncogene 21 (2002), 7298–7306.
69. Romeo, MS, Sokolova, IA, Morrison, LE, Zeng, C, Baron, AE, Hirsch, FR, Miller, YE, Franklin, WA, Varella-Garcia, M, Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn 5 (2003), 103–112.
70. de Boer, WI, Hau, CM, van Schadewijk, A, Stolk, J, van Krieken, JH, Hiemstra, PS, Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 125 (2006), 184–192.
71. Liu, K, Anderson, GP, Bozinovski, S, DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. Am J Respir Cell Mol Biol 39 (2008), 305–311.
72. Liu, K, Gualano, RC, Hibbs, ML, Anderson, GP, Bozinovski, S, Epidermal growth factor receptor signaling to Erk 1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem 283 (2008), 9977–9985.
73. Gustafson, AM, Soldi, R, Anderlind, C, Scholand, MB, Qian, J, Zhang, X, Cooper, K, Walker, D, McWilliams, A, Liu, G et al., Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med, 2, 2010, 26ra25d.
74. Drilon, A, Rekhtman, N, Ladanyi, M, Paik, P, Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 13 (2012), e418–e426.
75. Tang, JM, He, QY, Guo, RX, Chang, XJ, Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51 (2006), 181–191.
76. Lim, WT, Zhang, WH, Miller, CR, Watters, JW, Gao, F, Viswanathan, A, Govindan, R, McLeod, HL, PTEN and phosphorylated AKT expression and prognosis in early and late-stage non-–small cell lung cancer. Oncol Rep 17 (2007), 853–857.
77. Soria, JC, Lee, HY, Lee, JI, Wang, L, Issa, JP, Kemp, BL, Liu, DD, Kurie, JM, Mao, L, Khuri, FR, Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8 (2002), 1178–1184.
78. Guerra, C, Schumacher, AJ, Canamero, M, Grippo, PJ, Verdaguer, L, Pérez-Gallego, L, Dubus, P, Sandgren, EP, Barbacid, M, Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 (2007), 291–302.
79. Sumimoto, H, Imabayashi, F, Iwata, T, Kawakami, Y, The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203 (2006), 1651–1656.
80. Shchors, K, Shchors, E, Rostker, F, Lawlor, ER, Brown-Swigart, L, Evan, GI, The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β. Genes Dev 20 (2006), 2527–2538.
81. Birben, E, Sahiner, UM, Sackesen, C, Erzurum, S, Kalayci, O, Oxidative stress and antioxidant defense. World Allergy Organ J 5 (2012), 9–19.
82. Mikkelsen, RB, Wardman, P, Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 22 (2003), 5734–5754.
83. Kroncke, KD, Nitrosative stress and transcription. Biol Chem 384 (2003), 1365–1377.
84. Baron, JA, Sandler, RS, Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51 (2000), 511–523.
85. Sata, N, Klonowski-Stumpe, H, Han, B, Haussinger, D, Niederau, C, Cytotoxicity of peroxynitrite in rat pancreatic acinar AR4-2J cells. Pancreas 15 (1997), 278–284.
86. Hsu, IC, Metcalf, RA, Sun, T, Welsh, JA, Wang, NJ, Harris, CC, Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 (1991), 427–428.
87. Albring, M, Griffith, J, Attardi, G, Association of a protein structure of probable membrane derivation with HeLa cell mitochondrial DNA near its origin of replication. Proc Natl Acad Sci U S A 74 (1977), 1348–1352.
88. Federico, A, Morgillo, F, Tuccillo, C, Ciardiello, F, Loguercio, C, Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121 (2007), 2381–2386.
89. Pastukh, VM, Zhang, L, Ruchko, MV, Gorodnya, O, Bardwell, GC, Tuder, RM, Gillespie, MN, Oxidative DNA damage in lung tissue from patients with COPD is clustered in functionally significant sequences. Int J Chron Obstruct Pulmon Dis 6 (2011), 209–217.
90. Rahman, I, Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 1822 (2012), 714–728.
91. Hoffmann, D, Hoffmann, I, El-Bayoumy, K, The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14 (2001), 767–790.
92. Dekhuijzen, PN, Aben, KK, Dekker, I, Aarts, LP, Wielders, PL, van Herwaarden, CL, Bast, A, Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154 (1991), 813–816.
93. Malhotra, D, Thimmulappa, R, Navas-Acien, A, Sandford, A, Elliott, M, Singh, A, Chen, L, Zhuang, X, Hogg, J, Pare, P et al., Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 178 (2008), 592–604.
94. DeNicola, GM, Karreth, FA, Humpton, TJ, Gopinathan, A, Wei, C, Frese, K, Mangal, D, KH, Yu, Yeo, CJ, Calhoun, ES et al., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
95. Covey, TM, Edes, K, Coombs, GS, Virshup, DM, Fitzpatrick, FA, Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One, 5, 2010, e13545.
96. Garte, S, Metabolic susceptibility genes as cancer risk factors: time for a reassessment?. Cancer Epidemiol Biomarkers Prev 10 (2001), 1233–1237.
97. Ley, RE, Turnbaugh, PJ, Klein, S, Gordon, JI, Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006), 1022–1023.
98. Nadal, I, Santacruz, A, Marcos, A, Warnberg, J, Garagorri, JM, Moreno, LA, Martin-Matillas, M, Campoy, C, Martí, A, Moleres, A et al., Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes 33 (2009), 758–767.
99. Turnbaugh, PJ, Hamady, M, Yatsunenko, T, Cantarel, BL, Duncan, A, Ley, RE, Sogin, ML, Jones, WJ, Roe, BA, Affourtit, JP et al., A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
100. Sartor, RB, Microbial influences in inflammatory bowel diseases. Gastroenterology 134 (2008), 577–594.
101. Eckburg, PB, Bik, EM, Bernstein, CN, Purdom, E, Dethlefsen, L, Sargent, M, Gill, SR, Nelson, KE, Relman, DA, Diversity of the human intestinal microbial flora. Science 308 (2005), 1635–1638.
102. Bäckhed, F, Ley, RE, Sonnenburg, JL, Peterson, DA, Gordon, JI, Host-bacterial mutualism in the human intestine. Science 307 (2005), 1915–1920.
103. Chassaing, B, Etienne-Mesmin, L, Gewirtz, AT, Microbiota-liver axis in hepatic disease. Hepatology 59 (2014), 328–339.
104. Cariello, R, Federico, A, Sapone, A, Tuccillo, C, Scialdone, VR, Tiso, A, Miranda, A, Portincasa, P, Carbonara, V, Palasciano, G et al., Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 42 (2010), 200–204.
105. Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
106. Cho, I, Blaser, MJ, The human microbiome: at the interface of health and disease. Nat Rev Genet 13 (2012), 260–270.
107. Plottel, CS, Blaser, MJ, Microbiome and malignancy. Cell Host Microbe 10 (2011), 324–335.
108. Ogino, S, Stampfer, M, Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102 (2010), 365–367.
109. Ogino, S, Nosho, K, Meyerhardt, JA, Kirkner, GJ, Chan, AT, Kawasaki, T, Giovannucci, EL, Loda, M, Fuchs, CS, Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 26 (2008), 5713–5720.
110. Ogino, S, Chan, AT, Fuchs, CS, Giovannucci, E, Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60 (2011), 397–411.
111. Tilg, H, Moschen, AR, Food, immunity, and the microbiome. Gastroenterology 148 (2015), 1107–1119.
112. Rajpoot, M, Sharma, AK, Sharma, A, Gupta, GK, Understanding the microbiome: emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. Semin Cancer Biol, 2018 [S1044-579X:30146-3].
113. Routy, B, Le Chatelier, E, Derosa, L, Duong, CPM, Alou, MT, Daillère, R, Fluckiger, A, Messaudone, M, Rauber, C, Roberti, MP et al., Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359 (2018), 91–97.
114. Tahara, T, Yamamoto, E, Suzuki, H, Maruyama, R, Chung, W, Garriga, J, Jelinek, J, Yamano, HO, Sugai, T, An, B et al., Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74 (2014), 1311–1318.
115. Nosho, K, Sukawa, Y, Adachi, Y, Ito, M, Mitsuhashi, K, Kurihara, H, Kanno, S, Yamamoto, I, Ishigami, K, Igarashi, H et al., Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 22 (2016), 557–566.
116. Mima, K, Sukawa, Y, Nishihara, R, Qian, ZR, Yamauchi, M, Inamura, K, Kim, SA, Masuda, A, Nowak, JA, Nosho, K et al., Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 1 (2015), 653–661.
117. T, Yu, Guo, F, Y, Yu, Sun, T, Ma, D, Han, J, Qian, Y, Kryczek, I, Sun, D, Nagarsheth, N, Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170 (2017), 548–563.
118. Abreu, MT, Peek, RM Jr., Gastrointestinal malignancy and the microbiome. Gastroenterology 146 (2014), 1534–1546.
119. Peek, RM Jr., Blaser, MJ, Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2 (2002), 28–37.
120. Yang, L, Lu, X, Nossa, CW, Francois, F, Peek, RM, Pei, Z, Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137 (2009), 588–597.
121. Ferlay, J, Soerjomataram, I, Dikshit, R, Eser, S, Mathers, C, Rebelo, M, Parkin, DM, Forman, D, Bray, F, Cancer incidence and mortality world-wide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
122. Plummer, M, Franceschi, S, Vignat, J, Forman, D, de Martel, C, Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 136 (2015), 487–490.
123. Amieva, M, Peek, RM Jr., Pathobiology of Helicobacter pylori–induced gastric cancer. Gastroenterology 150 (2016), 64–78.
124. Wroblewski, LE, Peek, RM Jr., Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am 42 (2013), 285–298.
125. Miehlke, S, Kirsch, C, Agha-Amiri, K, Gunther, T, Lehn, N, Malfertheiner, P, Stolte, M, Ehninger, G, Bayerdörffer, E, The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 87 (2000), 322–327.
126. Andersson, AF, Lindberg, M, Jakobsson, H, Bäckhed, F, Nyrén, P, Engstrand, L, Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One, 3, 2008, e2836.
127. Correa, P, Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52 (1992), 6735–6740.
128. Eun, CS, Kim, BK, Han, DS, Kim, SY, Kim, KM, Choi, BY, Song, KS, Kim, YS, Kim, JF, Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 19 (2014), 407–416.
129. Yang, I, Woltemate, S, Piazuelo, MB, Bravo, LE, Yepez, MC, Romero-Gallo, J, Delgado, AG, Wilson, KT, Peek, RM, Correa, P et al., Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci Rep, 6, 2016, 18594.
130. Siegel, R, Desantis, C, Jemal, A, Colorectal cancer statistics, 2014. CA Cancer J Clin 64 (2014), 104–117.
131. Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA Jr., Kinzler, KW, Cancer genome landscapes. Science 339 (2013), 1546–1558.
132. Hagland, HR, Søreide, K, Cellular metabolism in colorectal carcinogenesis: influence of lifestyle, gut microbiome and metabolic pathways. Cancer Lett 356 (2016), 273–280.
133. Janakiram, NB, Rao, CV, The role of inflammation in colon cancer. Adv Exp Med Biol 816 (2014), 25–52.
134. Speed, N, Blair, IA, Cyclooxygenase- and lipoxygenase-mediated DNA damage. Cancer Metastasis Rev 30 (2011), 437–447.
135. Wang, X, Yang, Y, Huycke, MM, Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms. Free Radic Biol Med 105 (2017), 3–15.
136. Johnson, CH, Dejea, CM, Edler, D, Hoang, LT, Santidrian, AF, Felding, BH et al., Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab 21 (2015), 891–897.
137. Rubinstein, MR, Wang, X, Liu, W, Hao, Y, Cai, G, Han, YW, Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesion. Cell Host Microbe 14 (2013), 195–206.
138. Engle, SJ, Ormsby, I, Pawlowski, S, Boivin, GP, Croft, J, Balish, E, Doetschman, T, Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 62 (2002), 6362–6366.
139. Kado, S, Uchida, K, Funabashi, H, Iwata, S, Nagata, Y, Ando, M, Onoue, M, Matsuoka, Y, Ohwaki, M, Morotomi, M, Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001), 2395–2398.
140. Zhan, Y, Chen, PJ, Sadler, WD, Wang, F, Poe, S, Nuñez, G, Eaton, KA, Chen, GY, Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res 73 (2013), 7199–7210.
141. Man, SM, Zhu, Q, Zhu, L, Liu, Z, Karki, R, Malik, A, Sharma, D, Li, L, Malireddi, RK, Gurung, P, Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell 162 (2015), 45–58.
142. Couturier-Maillard, A, Secher, T, Rehman, A, Normand, S, De Arcangelis, A, Haesler, R, Huot, L, Grandjean, T, Bressenot, A, Delanoye-Crespin, A et al., NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Investig 123 (2013), 700–711.
143. Negroni, A, Cucchiara, S, Stronati, L, Apoptosis, necrosis, and necroptosis in the gut and intestinal homeostasis. Mediators Inflamm, 2015, 2015, 250762.
144. Loktionov, A, Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Cancer 120 (2007), 2281–2289.
145. Larsson, JM, Karlsson, H, Crespo, JG, Johansson, ME, Eklund, L, Sjovall, H, Hansson, JC, Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis 17 (2011), 2299–2307.
146. Prorok-Hamon, M, Friswell, MK, Alswied, A, Roberts, CL, Song, F, Flanagan, PK, Knight, P, Codling, C, Marchesi, JR, Winstanley, C et al., Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 63 (2014), 761–770.
147. Dejea, CM, Wick, EC, Hechenbleikner, EM, White, JR, Mark Welch, JL, Rossetti, BJ, Peterson, SN, Snesrud, EC, Borisy, GG, Lazarev, M et al., Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A 111 (2014), 18321–18326.
148. Wang, X, Huycke, MM, Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132 (2007), 551–561.
149. Kim, JM, Lee, JY, Yoon, YM, Oh, YK, Kang, JS, Kim, YJ, Kim, KH, Bacteroides fragilis enterotoxin induces cyclooxygenase-2 and fluid secretion in intestinal epithelial cells through NF-kappaB activation. Eur J Immunol 36 (2006), 2446–2456.
150. Fukata, M, Abreu, MT, Role of toll-like receptors in gastrointestinal malignancies. Oncogene 27 (2008), 234–243.
151. Fukata, M, Chen, A, Klepper, A, Krishnareddy, S, Vamadevan, AS, LS Thomas, R Xu, Inoue, H, Arditi, M, Dannenberg, AJ et al., Cox-2 is regulated by Toll-like Receptor-4 (TLR4) signaling: role in proliferation and Apoptosis in the intestine. Gastroenterology 131 (2006), 862–877.
152. Schirbel, A, Kessler, S, Rieder, F, West, G, Rebert, N, Asosingh, K, McDonald, C, Fiocchi, C, Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology, 144, 2013, 613-623.e9.
153. Boonanantanasarn, K, Gill, AL, Yap, Y, Jayaprakash, V, Sullivan, MA, Gill, SR, Enterococcus faecalis enhances cell proliferation through hydrogen peroxide-mediated epidermal growth factor receptor activation. Infect Immun 80 (2012), 3545–3558.
154. Kim, JM, Lee, JY, Kim, YJ, Inhibition of apoptosis in Bacteroides fragilis enterotoxin-stimulated intestinal epithelial cells through the induction of c-IAP-2. Eur J 38 (2008), 2190–2199.
155. Mehlen, P, Delloye-Bourgeois, C, Chédotal, A, Novel roles for Slits and netrins: axon guidance cues as anticancer targets?. Nat Rev Cancer 11 (2001), 188–197.
156. Ferlay, J, Soerjomataram, I, Ervik, M, Dikshit, R, Eser, S, Mathers, C, Rebelo, M, Parkin, DM, Forman, D, Bray, F, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]., International Agency for Research on Cancer, Lyon, France, 2013 [cited 2017 Dec 1]. Available from http://globocan.iarc.fr.
157. De Minicis, S, Rychlicki, C, Agostinelli, L, Saccomanno, S, Candelaresi, C, Trozzi, L, Mingarelli, E, Facinelli, B, Magi, G, Palmieri, C et al., Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59 (2014), 1738–1749.
158. Son, G, Kremer, M, Hines, IN, Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract, 2010, 2010.
159. Liaskou, E, Wilson, DV, Oo, YH, Innate immune cells in liver inflammation. Mediators Inflamm, 2012, 2012, 949157.
160. Tsiaoussis, GI, Assimakopoulos, SF, Tsamandas, AC, Triantos, CK, Thomopoulos, KC, Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol 7 (2015), 2058–2068.
161. Darnaud, M, Faivre, J, Moniaux, N, Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58 (2013), 385–387.
162. Roh, YS, Seki, E, Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 28:Suppl. 1 (2013), 38–42.
163. Dapito, DH, Mencin, A, Gwak, GY, Pradere, JP, Jang, MK, Mederacke, I, Caviglia, JM, Khiabanian, H, Adeyemi, A, Bataller, R et al., Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
164. Elinav, E, Nowarski, R, Thaiss, CA, Hu, B, Jin, C, Flavell, RA, Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13 (2013), 759–771.
165. Stickel, F, Hellerbrand, C, Nonalcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59 (2010), 1303–1307.
166. Schnabl, B, Purbeck, CA, Choi, YH, Hagedorn, CH, Brenner, D, Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 37 (2003), 653–664.
167. Yoshimoto, S, Loo, TM, Atarashi, K, Kanda, H, Sato, S, Oyadomari, S, Iwakura, Y, Oshima, K, Morita, H, Hattori, M et al., Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
168. Mitsuhashi, K, Nosho, K, Sukawa, Y, Matsunaga, Y, Ito, M, Kurihara, H, Kanno, S, Igarashi, H, Naito, T, Adachi, Y et al., Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6 (2015), 7209–7220.
169. Zambirinis, CP, Pushalkar, S, Saxena, D, Miller, G, Pancreatic cancer, inflammation, and microbiome. Cancer J 20 (2014), 195–202.